Healthcare investor Apposite Capital has invested in medical device company, Emblation, to support its international growth and broaden its go-to market offering.
Created in 2007 by Gary Beale and Eamon McErlean, Emblation designs, manufactures and commercialises next generation microwave-based solutions for a range of skin conditions. The award-winning and clinically proven technology, SWIFT, offers a non-ablative treatment for common and plantar warts. Emblation’s products are also used in the treatment of certain cancers. Emblation’s systems are currently sold in the UK, North America and Australia, and have been used in over 130,000 treatments to date.
Alongside the investment, Jim Atkinson, former VP Sales of Ulthera Inc, a prior Apposite Capital portfolio company focused on aesthetic medical devices, has been appointed to the Emblation Board together with Rory Pope, partner, Apposite Capital.
Commenting on this final platform investment from Apposite Healthcare Fund II, Rory Pope said: “We are delighted to support a business that is delivering an enhanced patient experience and superior results in the fields of podiatry and dermatology. SWIFT’s low energy microwave technology is unique and Emblation is well-positioned to continue delivering clinical breakthroughs and growth in adjacent pre-cancerous and cancerous indications. We are looking forward to working with Gary and the team as Emblation enters the next phase of its growth.”
Gary Beale, CEO, added: “We are pleased to have secured an investment from Apposite Capital which will allow us to accelerate our international expansion into new and existing markets as well as continue to build on our technology platform and deliver ground-breaking clinical results. Apposite immediately recognised the growth potential of our technology, and I am particularly excited to be working with the firm given their understanding of the sector and their expertise in scaling-up businesses like ours.”
